TITAN PHARMACEUTICALS INC — Director's Dealing 2016

Feb 23, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TITAN PHARMACEUTICALS INC (TTNP)
CIK: 0000910267
Period of Report: 2016-02-22

Reporting Person: BHONSLE SUNIL (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-02-22	Common Stock	P	11763	$3.555	Acquired	125578	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	54684	Indirect

Footnotes

F1: Represents the weighted average purchase price for the reported transactions. The range of prices for such transactions was $3.50 to $3.61. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F2: The reporting person serves as trustee of the family trust.